Home › Modalities › Gene Therapy

Gene Therapy (24 companies)

Ticker	Company	Therapeutic areas	Programs	Lead stage	Mkt cap	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	5	Phase 3	$677M	5
BEAM	Beam Therapeutics	HematologyMetabolic+1 Rare	1	Phase 2	$2.73B	6
CADL	Candel Therapeutics	Oncology	4	Phase 3	$670M	4
CGON	CG Oncology	Oncology	1	NDA Submitted	$6.79B	1
GNLX	Genelux	Oncology	3	Phase 3	$88.7M	3
IBRX	ImmunityBio	Infectious DiseaseOncology	3	Approved	$9.15B	16
INSM	Insmed	CardiovascularImmunology+3 Rare	2	Approved	$25.1B	15
NTLA	Intellia Therapeutics	CardiovascularImmunology Rare	3	NDA Submitted	$1.59B	3
LXEO	Lexeo Therapeutics	CardiovascularNeurology Rare	8	Phase 2	$237M	12
MGTX	MeiraGTx	ImmunologyMetabolic+2 Rare	16	Phase 3	$864M	16
NGNE	Neurogene	Neurology Rare	1	Phase 3	$506M	1
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	8	Phase 3	$314M	12
ONCY	Oncolytics Biotech	Oncology	3	Phase 2	$56.1M	3
IRD	Opus Genetics	Ophthalmology Rare	8	Approved	$348M	12
DTIL	Precision Biosciences	Infectious DiseaseMetabolic+1 Rare	4	Phase 1	$296M	5
REPL	Replimune Group	Oncology	5	Approved	$2.05B	5
RCKT	Rocket Pharmaceuticals	CardiovascularImmunology Rare	4	Approved	$262M	4
SANA	Sana Biotechnology	MetabolicOncology	2	Phase 1	$710M	4
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	2	Approved	$1.91B	11
SLDB	Solid Biosciences	CardiovascularNeurology Rare	6	Phase 3	$736M	6
TSHA	Taysha Gene Therapies	Neurology Rare	4	Phase 3	$1.41B	4
RARE	Ultragenyx Pharmaceutical	CardiovascularMetabolic+1 Rare	3	Approved	$1.57B	10
QURE	uniQure	HematologyMetabolic+1 Rare	4	Approved	$1.52B	4
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	4	Phase 1	$116M	9